Black Diamond Therapeutics (BDTX) EBITDA (2018 - 2026)

Black Diamond Therapeutics (BDTX) has reported EBITDA for 9 consecutive years, with -$12.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA rose 10.16% year-over-year to -$12.1 million; the trailing twelve-month figure through Jun 2026 stood at -$51.9 million (down 1203.17% YoY), and the FY2025 full-year result was $12.5 million, up 115.89% from the prior year.
• EBITDA retreated to -$12.1 million in Q2 2026 per BDTX's latest filing, from -$11.3 million in the prior quarter.
• Across five years, EBITDA topped out at $54.5 million in Q1 2025 and bottomed at -$25.7 million in Q1 2022.
• Historically, EBITDA has averaged -$14.9 million across 5 years, with a median of -$20.1 million in 2023.
• The sharpest annual moves came in 2025 and 2026: EBITDA jumped 369.34% in 2025, then tumbled 120.65% in 2026.
• Over 5 years, EBITDA stood at -$21.9 million in 2022, then advanced by 4.56% to -$20.9 million in 2023, then climbed by 12.37% to -$18.3 million in 2024, then advanced by 3.64% to -$17.6 million in 2025, then soared by 31.53% to -$12.1 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$12.1 million, -$11.3 million, and -$17.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.